Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

202014 citationsJournal Articlegreen Open Access

Authors

Michael A. Nauck

Peter Lommer Kristensen

Lasse Steen Ravn

Richard M. Bergenstal

Kirstine Brown Frandsen

John B. Buse · University of North Carolina at Chapel Hill

Johannes F.E. Mann

Abstract

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Hyperglycemia and glycemic control in critically ill and hospitalized patients

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: UNC Libraries

DOI: 10.17615/5vsp-zn15

Field-Weighted Citation Impact: 0.99